News Could microplastics be linked to cardiovascular disease? People who have a heart attack are more likely to have microplastics in their blood, adding to evidence that plastic pollution may be a health issue.
News Scribe Therapeutics joins the IPO queue Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq as it advances its spin on CRISPR-based therapeutics.
News Ionis' Tryngolza claims critical label expansion in US Ionis' Tryngolza has been approved for severe hypertriglyceridaemia, opening the door to what the company thinks could be a $3bn market opportunity.
News Heart drug biotech Kardigan raises $400m in upscaled IPO Cardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated.
News Bayer's asundexian starts EU review for ischaemic stroke The EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J&J.
News Heart drug developer Kardigan files IPO The steady stream of biotech IPOs on the Nasdaq this year has continued, with Kardigan the latest to make its intention to list known.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.